Ravi Vemuri, MD
Infectious Disease · Des Moines, IANPI 1154307536
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,500 of the $16,302 with a category attached, or 82.8%. Sanofi Pasteur Inc. accounts for 97.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $10,270 and has fallen 99.6% since, to $39 in 2025. Among infectious disease clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 40 payments — averaging $407.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi Pasteur Inc.$16K
- Merck$147
- Osiris Therapeutics Inc.$122
- Astellas Pharma US Inc$90
- Insmed, Inc.$30
- Aimmune Therapeutics, Inc.$25
- plus $15 from 1 others
What the payments were for
- Speaking & faculty fees$13,50083%
- Travel & lodging$1,70810%
- Food & beverage$9896%
- Education$1061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi Pasteur Inc. | 32 | $15,873 |
| Merck | 1 | $147 |
| Osiris Therapeutics Inc. | 1 | $122 |
| Astellas Pharma US Inc | 2 | $90 |
| Insmed, Inc. | 2 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLUZONE HIGH-DOSE$15,240
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$5,092
- FLUBLOK QUADRIVALENT$4,845
- DIFICID$147
- ZINPLAVA$147
- Stravix$122
- Grafix$122
- GrafixPL$122
How this compares
$16,302 in reported general payments places this provider in the 95th percentile of 58 infectious disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 96 | $407,027 |
| JulucaDolutegravir/Rilpivirine | 12 | $39,618 |
| TivicayDolutegravir Sodium | 16 | $33,971 |
| Daptomycin | 38 | $11,349 |
| Cefepime Hcl | 28 | $3,661 |
| CeftriaxoneCeftriaxone Sodium | 33 | $2,257 |
| Rifampin | 11 | $807 |
| Cefazolin Sodium | 11 | $728 |
| Doxycycline Hyclate | 31 | $634 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $300 |
| Penicillin V Potassium | 12 | $128 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $34 |
| Levofloxacin | 12 | $16 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Des Moines
- Aneesa AfrozeDes Moines$1K
- Rima El-HerteDes Moines$901
- David Terrero SalcedoDes Moines$873
- Casey RiceDes Moines$231
- Roger HarveyDes Moines$50
- Francisco Rincon BoscanDes Moines$49
- Sudhir KumarDes Moines$32
- James HalseyDes Moines$25
- Lisa VeachDes Moines$16
- Roshan LewisDes Moines$16
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.